{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:49:48Z","timestamp":1776228588816,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000313","name":"British Society for Antimicrobial Chemotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Menarini"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monitoring the real-world use of recently licensed antimicrobials (RLAs) is critical for antimicrobial stewardship. Traditional surveillance systems are resource-intensive and limited in scope.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The UK Antimicrobial Registry: Virtual Registry (UKAR:V) was established to determine whether routinely collected electronic healthcare data can generate robust, national-level evidence on the utilization, effectiveness and safety of RLAs in Scotland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This registry used linked data from Scotland\u2019s Hospital Electronic Prescribing and Medicines Administration system and national datasets. Adults (\u226518\u2005years) prescribed any of 11 RLAs (cefiderocol, ceftazidime\/avibactam, ceftolozane\/tazobactam, meropenem\/vaborbactam, imipenem\/cilastatin\/relebactam, eravacycline, ceftaroline, ceftobiprole, dalbavancin, delafloxacin, oritavancin) between June 2019 and June 2023 were included. Descriptive analyses summarized patient characteristics, prescribing patterns, infection types, microbiology results and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 308 patients received 353 RLA prescriptions. Dalbavancin was commonly prescribed (70.5%), followed by ceftazidime\/avibactam (13.3%). Microbiology results were available for 35% of patients. Pseudomonas aeruginosa (43.7%) and Klebsiella pneumoniae (19.5%) were the most common isolates for Gram-negative RLAs, while Staphylococcus aureus (50%) predominated among Gram-positive RLAs. Gram-negative RLAs were mainly used for severe respiratory and sepsis cases, whereas dalbavancin was used for skin, soft-tissue and device-related infections. Median treatment duration ranged from 7 to 12\u2005days for Gram-negative RLAs and one dose for dalbavancin. Twenty-eight-day readmission was 25%\u201340% for Gram-negative RLAs and 29.8% for Gram-positive RLAs, while 6-month relapse ranged from \u223c38% to 67% and 51.7%, respectively. No major linkage issues\/failures were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>UKAR:V shows that linked electronic data can support real-world RLA surveillance. With appropriate data linkage, this model offers a scalable, low-burden approach to monitoring utilization\/outcomes providing a sustainable foundation for stewardship\/policy and assessment of innovative reimbursement models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag053","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:43:26Z","timestamp":1774701806000},"source":"Crossref","is-referenced-by-count":0,"title":["UK Antimicrobial Registry: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland"],"prefix":"10.1093","volume":"8","author":[{"given":"Cosmika","family":"Goswami","sequence":"first","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow G4 0RE ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru","family":"Turgal","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow G4 0RE ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-4789","authenticated-orcid":false,"given":"Tanja","family":"Mueller","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow G4 0RE ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-629X","authenticated-orcid":false,"given":"Marion","family":"Bennie","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow G4 0RE ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Parr","sequence":"additional","affiliation":[{"name":"Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen , Aberdeen ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-7591","authenticated-orcid":false,"given":"Gareth T","family":"Jones","sequence":"additional","affiliation":[{"name":"Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen , Aberdeen ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Andrew","family":"Seaton","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , Birmingham ,","place":["UK"]},{"name":"Infectious Diseases Unit, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, University Hospitals of Leicester NHS Trust , Leicester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-4835","authenticated-orcid":false,"given":"Ioannis","family":"Baltas","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , Birmingham ,","place":["UK"]},{"name":"Department of Infection, Immunity and Inflammation, Institute of Child Health, University College London , London ,","place":["UK"]},{"name":"Department of Microbiology, University College Hospital, University College London Hospitals NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Sneddon","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , Birmingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-8677","authenticated-orcid":false,"given":"Jonathan A T","family":"Sandoe","sequence":"additional","affiliation":[{"name":"Healthcare Associated Infection Group, Leeds Institute of Medical Research, University of Leeds and Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Garraghan","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , Birmingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M","family":"Brown","sequence":"additional","affiliation":[{"name":"Clinical Microbiology & Public Health Laboratory, Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-3314","authenticated-orcid":false,"given":"Gary J","family":"Macfarlane","sequence":"additional","affiliation":[{"name":"Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen , Aberdeen ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-1988","authenticated-orcid":false,"given":"Amanj","family":"Kurdi","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow G4 0RE ,","place":["UK"]},{"name":"College of Pharmacy, Al-Kitab University , Kirkuk 36015 ,","place":["Iraq"]},{"name":"Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University , Pretoria ,","place":["South Africa"]},{"name":"College of Pharmacy, Hawler Medical University , Erbil, Kurdistan Region ,","place":["Iraq"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026041423534949600_dlag053-B1","doi-asserted-by":"crossref","DOI":"10.2471\/B09585","volume-title":"Global Antibiotic Resistance Surveillance Report 2025: WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS)","author":"World Health Organization","year":"2025"},{"key":"2026041423534949600_dlag053-B2","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.2147\/IDR.S530557","article-title":"Antimicrobial resistance: a rising global threat to public health","volume":"18","author":"Patra","year":"2025","journal-title":"Infect Drug Resist"},{"key":"2026041423534949600_dlag053-B3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2026041423534949600_dlag053-B4","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae107","article-title":"Introducing the UK antimicrobial registry (UKAR) study: providing real world data on new antimicrobials to support antimicrobial stewardship and tackle antimicrobial resistance","volume":"6","author":"Sneddon","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026041423534949600_dlag053-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212600","article-title":"Challenges and research priorities to progress the impact of antimicrobial stewardship","volume":"8","author":"Bassetti","year":"2019","journal-title":"Drugs Context"},{"key":"2026041423534949600_dlag053-B6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026041423534949600_dlag053-B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/antibiotics13040327","article-title":"Dalbavancin for acute bacterial skin and skin structure infections in pediatrics: insights from continuation therapy experience","volume":"13","author":"Scarano","year":"2024","journal-title":"Antibiotics"},{"key":"2026041423534949600_dlag053-B8","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1128\/AAC.01653-08","article-title":"Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections","volume":"53","author":"Kimko","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041423534949600_dlag053-B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2023.1010247","article-title":"Recent advances in addressing the market failure of new antimicrobials: learnings from NICE's subscription-style payment model","volume":"5","author":"Schurer","year":"2023","journal-title":"Front Med Tech"},{"key":"2026041423534949600_dlag053-B10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/bcp.14184","article-title":"Improving prescribing through big data approaches\u2014ten years of the Scottish prescribing information system","volume":"86","author":"Bennie","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026041423534949600_dlag053-B11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14787210.2023.2181789","article-title":"Evaluation of duration of antibiotic therapy across hospitals in Scotland including the impact of COVID-19 pandemic: a segmented interrupted time series analysis","volume":"21","author":"Kurdi","year":"2023","journal-title":"Expert Rev Anti Infective Ther"},{"key":"2026041423534949600_dlag053-B12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/jac\/dkw528","article-title":"Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case\u2013control study using administrative data","volume":"72","author":"Kavanagh","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026041423534949600_dlag053-B13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/jac\/dkx363","article-title":"Risk factors for resistance and MDR in community urine isolates: population-level analysis using the NHS Scotland infection intelligence platform","volume":"73","author":"Malcolm","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026041423534949600_dlag053-B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijantimicag.2011.02.005","article-title":"Scottish antimicrobial prescribing group (SAPG): development and impact of the Scottish national antimicrobial stewardship programme","volume":"38","author":"Nathwani","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2026041423534949600_dlag053-B15","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.infpip.2023.100315","article-title":"Challenges of implementing antimicrobial stewardship tools in Low to Middle Income Countries (LMICs)","volume":"5","author":"Shamas","year":"2023","journal-title":"Infect Prev Pract"},{"key":"2026041423534949600_dlag053-B16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/14740338.2022.2106368","article-title":"Tackling antimicrobial resistance across sub-Saharan Africa: current challenges and implications for the future","volume":"21","author":"Godman","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"2026041423534949600_dlag053-B17","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1017\/S0950268825000263","article-title":"Data for action\u2013description of the automated COVID-19 surveillance system in Denmark and lessons learnt, January 2020 to June 2024","volume":"153","author":"Witteveen-Freidl","year":"2025","journal-title":"Epidemiol Infect"},{"key":"2026041423534949600_dlag053-B18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2147\/CLEP.S487838","article-title":"The Danish national hospital medication register: a resource for pharmacoepidemiology","volume":"16","author":"Rosenkrantz","year":"2024","journal-title":"Clin Epidemiol"},{"key":"2026041423534949600_dlag053-B19","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.23889\/ijpds.v8i6.2182","article-title":"Data resource profile: the hospital electronic prescribing and medicines administration (HEPMA) national data collection in Scotland","volume":"8","author":"Mueller","year":"2023","journal-title":"Int J Popul Data Sci"},{"key":"2026041423534949600_dlag053-B20","author":"Public Health Scotland","year":"2025"},{"key":"2026041423534949600_dlag053-B21","author":"Public Health Scotland","year":"2025"},{"key":"2026041423534949600_dlag053-B22","author":"Public Health Scotland","year":"2025"},{"key":"2026041423534949600_dlag053-B23","author":"Public Health Scotland"},{"key":"2026041423534949600_dlag053-B24","author":"Public Health Scotland","year":"2025"},{"key":"2026041423534949600_dlag053-B25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jphys.2016.05.008","article-title":"Charlson comorbidities index","volume":"62","author":"Roffman","year":"2016","journal-title":"J Physiother"},{"key":"2026041423534949600_dlag053-B26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jgar.2021.03.025","article-title":"Real-life experience with ceftolozane\/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry","volume":"25","author":"Zhanel","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2026041423534949600_dlag053-B27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J AntimicroChemother"},{"key":"2026041423534949600_dlag053-B28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Seaton","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026041423534949600_dlag053-B29","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf242","article-title":"The UK Antimicrobial Registry (UKAR): an overview of the first 20 months of recruitment","volume":"7","author":"Sneddon","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"2026041423534949600_dlag053-B30","volume-title":"Global Action Plan on Antimicrobial Resistance","author":"World Health Organization","year":"2015"},{"key":"2026041423534949600_dlag053-B31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the Swedish prescribed drug register\u2013a systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026041423534949600_dlag053-B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1058","article-title":"Antimicrobial resistance: UK\u2019s five year plan aims to reduce antibiotic use by 5% by 2029","volume":"385","author":"Murphy","year":"2024","journal-title":"BMJ"},{"key":"2026041423534949600_dlag053-B33","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S1473-3099(22)00683-1","article-title":"The WHO AWaRe antibiotic book: providing guidance on optimal use and informing policy","volume":"22","author":"Sharland","year":"2022","journal-title":"Lancet Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/2\/dlag053\/68080240\/dlag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/2\/dlag053\/68080240\/dlag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T03:53:55Z","timestamp":1776225235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag053\/8654002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag053","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,9]]},"article-number":"dlag053"}}